Compare DexCom, Inc. (DXCM) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Enovix Corporation — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Enovix Corporation trades at $4.56 (market cap $1.06B). The key difference: DexCom, Inc. is far larger — about 31.9× Enovix Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| DXCM | ENVX | |
|---|---|---|
Market Cap | $33.79B | $1.06B |
Sector | Health | Technology |
52-Week High | $89.53 | $13.19 |
52-Week Low | $54.84 | $3.68 |
Enterprise Value | $33.24B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
ENVX trades at $4.73, up 1.94% with a bullish technical signal despite negative profitability metrics. The company shows consistent earnings beats but operates at significant losses with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple executive as COO and upcoming Q2 2026 earnings on August 12, 2026.
Analyst consensus remains strongly bullish with a $12.38 price target (162% upside), though execution risks are high given cash burn and negative margins. The stock offers speculative growth potential in advanced battery technology but requires careful risk management due to ongoing operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
